News & Events about Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) CEO N Anthony Coles sold 50,000 shares of the businesss stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $29.94, for a total transaction of $1,497,000.00. Following the...
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has earned a consensus recommendation of Moderate Buy from the ten analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event:...
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarterEPS results and filed for a mixed-securities shelf offering of up to $900 million.
read more...
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) has been given an average rating of Moderate Buy by the eight brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy ...